AddedRisk Factors
•increased costs and decreased availability of raw materials or supplies, including due to tariffs; and
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedRisk Factors
We cannot guarantee that we will repurchase our common stock pursuant to our share repurchase program or that our share repurchase program will enhance long-term stockholder value. Share repurchases could also increase the volatility of the price of our common stock and could diminish our cash reserves.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedRisk Factors
On November 4, 2025, we announced that our Board of Directors had approved a share repurchase program with no expiration date, under which we are authorized to repurchase shares of common stock for up to $200 million on the open market, in privately-negotiated purchases, including accelerated share repurchases, or otherwise. As of December 31, 2025, approximately $150 million remained available under the program.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedRisk Factors
Although the Board of Directors has authorized the share repurchase program, the share repurchase program does not obligate the Company to repurchase any specific dollar amount or to acquire any specific number of shares. The timing and amount of repurchases will depend upon several factors, including market and business conditions, the trading price of our common stock and the nature of other investment opportunities. Our ability to repurchase shares of stock may be limited by restrictive covenants in our debt agreements and in the indentures governing the 2028 Convertible Notes and 2030 Convertible Notes. The repurchase program may be limited, suspended or discontinued at any time without prior notice. Repurchases of our common stock pursuant to our share repurchase program could affect our stock price and increase its volatility. Additionally, our share repurchase program could diminish our cash reserves, which may impact our ability to finance future growth and to pursue possible future strategic opportunities and acquisitions. Although our share repurchase program is intended to enhance long-term stockholder value, there is no assurance that it will do so.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RemovedRisk Factors
If a conversion request occurs, we have the intent and ability to refinance the amounts that may become due with respect to the 2028 Convertible Notes using available borrowing capacity under the Revolving Credit Facility. As such, the obligations associated with the 2028 Convertible Notes were classified as a long-term liability on the Consolidated Balance Sheets as of December 31, 2024. As of December 31, 2024, the borrowing capacity under our Revolving Credit Facility was $668.7 million, which exceeded the $500.0 million outstanding principal amount of the 2028 Convertible Notes. Even if holders of the 2028 Convertible Notes do not elect to convert their notes, or if our available borrowing capacity under our Revolving Credit Facility were to fall below the outstanding principal amount of the 2028 Convertible Notes, we could be required under applicable accounting rules to reclassify all or a portion of the outstanding principal of the 2028 Convertible Notes as a current rather than long-term liability, which would result in a material reduction of our net working capital.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RewordedRisk Factors
Our business is also subject to potential increased costs and expenses and others other risks resulting from existing and potential future U.S. and foreign legislation, regulations regulations, trade agreements, tariffs, trade wars, import restrictions, boycotts, embargoes, government investigations, trade policies and trade agreements compliance matters relating to the products we manufacture outside of the U.S and import into the U.S. and other materials we import, import for the production of products, including the tariffs on steel and copper that the U.S. has imposed, the imposed and other tariffs that the new current U.S. presidential administration has imposed or threatened to impose, particularly relating to imports into the U.S. from Canada, Mexico (where we currently manufacture a significant portion of our products) and China, Ireland, and other quotas, duties, tariffs or taxes or restrictions on imports, all or any of which could adversely affect our operations, increase the costs of products that we manufacture outside the U.S. or adversely impact our profits or margins. China.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
If an event (including any weather weather, natural disaster or natural disaster-related event adverse climate change-related events, war or terrorism, civil unrest, disruption in utilities and other services affecting our facilities or a resurgence future pandemic, epidemic, outbreak of the COVID-19 pandemic a contagious disease or other similar pandemic event) public health crisis) occurred that resulted in material damage, loss or incapacitation of one or more of these manufacturing facilities or if we lacked sufficient labor to fully operate any of our facilities, we may not be able to transfer the manufacture of the relevant products to another facility or location in a cost-effective or timely manner, if at all. all, which could materially and adversely affect our business.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
In either case, and in other cases, our obligations under the 2028 Convertible Notes and Notes, the 2030 Convertible Notes, the indenture governing the 2028 Convertible Notes could increase the cost of acquiring us or otherwise discourage a third party from acquiring us or removing incumbent management, including in a transaction that holders of our common stock may view as favorable.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
Additionally, new products and technologies that we develop may not be rapidly accepted because of industry-specific factors, including the need for regulatory clearance, entrenched patterns of clinical practice and practice, uncertainty over third-party reimbursement, reimbursement and our competitors developing products that provide better features, clinical outcomes or economic value than those that we currently offer or subsequently develop, and we may not be able to recover all or a meaningful part of our investment in the new products and technologies.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
The holders of our 2028 Convertible Notes have had the ability to, and may in the future continue to have the ability to, convert their notes at their option prior to the scheduled maturities and the holders of our 2030 Convertible Notes may in the future have the ability to convert their notes at their option prior to the scheduled maturities.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our failure to comply with applicable government regulations could also result in cessation of portions or all of our operations, impositions of fines and restrictions on our ability to carry on or expand our operations. operations, seizures or recalls of our products or those of our customers, inability to sell our products and adverse publicity affecting both us and our customers.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our 2028 In addition, our 2030 Convertible Notes have in the past been and currently are through March 31, 2025, and may in the future become, will become convertible at the option of their holders under certain circumstances.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
Whether the 2028 Convertible Notes or the 2030 Convertible Notes will be convertible in any future period will depend on the satisfaction satisfaction, with respect to the 2028 Convertible Notes, of this condition or or, with respect to the 2030 Convertible Notes, another conversion condition at such time.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
Certain provisions of the Inflation Reduction One Big Beautiful Bill Act passed in 2022, (OBBA), including a 15% corporate alternative minimum tax, Net CFC Tested Income (formerly GILTI), as well as the similar 15% global minimum tax under the Organization for Economic Co-operation and Development (“OECD”) Pillar Two Global Anti-Base Erosion Rules, may impact our income tax expense, profitability, and capital allocation decisions and may negatively impact our effective tax rate.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
The option counterparties for the capped call transactions for the 2028 Convertible Notes and the 2030 Convertible Notes are financial institutions, and we will be subject to the risk that any or all of them might default under the with respect to any such capped call transactions.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
Due to the complex nature of our business, and due to policies we have in place allowing certain of our employees to work from home from time to time, we are increasingly dependent upon our technology systems to operate our business and our ability to effectively manage our business depends on the security, reliability and adequacy of our technology systems and data.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our The price of our common stock may fluctuate significantly for numerous reasons, including the fluctuation of our operating results results, which have fluctuated in the past and are likely to continue to fluctuate from quarter to quarter, making forecasting future performance difficult and resulting in volatility in our common stock price.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
We depend heavily on a limited number of customers, and if we lose any of them or they significantly reduce their business with us, we would lose a substantial portion of our revenues.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
In addition, certain governmental and non-governmental organizations are enhancing or advancing requirements specific to ESG matters.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
In 2026, we expect sales growth to be impacted by lower sales related to three new products due to lower than anticipated market adoption. We believe the magnitude of these changes on multiple products at the same time is highly unusual.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
2030 Convertible Notes Issuance and 2028 Convertible Notes Exchange Transactions
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
On March 18, 2025, we issued $1.0 billion in aggregate principal amount of 1.875% Convertible Senior Notes due in 2030 (the “2030 Convertible Notes”). The total net proceeds from the issuance of the 2030 Convertible Notes, after deducting initial purchasers' discounts and commissions and debt issuance costs, were $976.1 million. We used $71.0 million of the net proceeds from the offering to fund the cost of entering into capped call transactions relating to the 2030 Convertible Notes.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
We used a portion of the remaining net proceeds from the issuance of the 2030 Convertible Notes to exchange $383.7 million in aggregate principal amount of our outstanding 2.125% Convertible Senior Notes due in 2028 (the “2028 Convertible Notes” and together with the “2030 Convertible Notes” the “Convertible Notes”) for an aggregate cash exchange consideration of $384.4 million in cash and 1,553,806 shares of common stock (the “Note Exchange Transactions”). The Note Exchange Transactions were considered an induced conversion and, as a result, we recorded $46.7 million during 2025 in induced conversion expense within Other loss, net in the Consolidated Statements of Operations. Contemporaneously with the Note Exchange Transactions, we terminated a portion of the capped call transactions related to the 2028 Convertible Notes and received 436,963 shares of common stock. We allotted the remainder of the net proceeds to pay the down our revolving credit facility and five-year “term A” loan.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
On December 4, 2025, we acquired certain assets of Biocoat. Prior to the acquisition, Biocoat was a privately-held manufacturer specializing in high value surface coating technology platforms, including UV and thermal cure hydrophilic coatings.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
On February 28, 2025, we acquired substantially all of the assets and assumed certain liabilities of VSi . Prior to the acquisition, VSi was a privately-held full-service provider of parylene coating solutions, primarily focused on complex medical device applications.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
The following table presents selected financial information derived from our Consolidated Financial Statements, contained in Item 8, “Financial Statements and Supplementary Data,” of this report, for the periods presented (dollars in thousands, except per share amounts):Change 2025 vs. 2024 2025 2024 $ % Cardio & Vascular $ 1,107,084 $ 949,576 $ 157,508 16.6% Cardiac Rhythm Management & Neuromodulation 668,803 660,610 8,193 1.2% Other Markets 77,750 106,410 (28,660) (26.9)% Total sales 1,853,637 1,716,596 137,041 8.0% Cost of sales 1,353,251 1,257,582 95,669 7.6% Gross profit 500,386 459,014 41,372 9.0% Gross profit as a % of sales 27.0 % 26.7 % Operating expenses: Selling, general and administrative 211,748 185,202 26,546 14.3% SG&A as a % of sales 11.4 % 10.8 % Research, development and engineering 49,499 53,425 (3,926) (7.3)% RD&E as a % of sales 2.7 % 3.1 % Restructuring and other charges 17,875 12,149 5,726 47.1% Total operating expenses 279,122 250,776 28,346 11.3% Operating income 221,264 208,238 13,026 6.3% Operating expense as a % of sales 15.1 % 14.6 % Operating income as a % of sales (“Operating margin”) 11.9 % 12.1 % Interest expense 43,206 56,374 (13,168) (23.4)% (Gain) loss on equity investments, net (550) 780 (1,330) NM Other loss, net 53,212 3,521 49,691 NM Income from continuing operations before income taxes 125,396 147,563 (22,167) (15.0)% Provision for income taxes 22,566 26,510 (3,944) (14.9)% Effective tax rate 18.0 % 18.0 % Income from continuing operations $ 102,830 $ 121,053 $ (18,223) (15.1)% Income from continuing operations as a % of sales 5.5 % 7.1 % Diluted earnings per share from continuing operations $ 2.89 $ 3.40 $ (0.51) (15.0)%
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
The following discussion is a comparison between results for the years ended December 31, 2025 and 2024. For a discussion of our results of operations for the year ended December 31, 2024 compared to the year ended December 31, 2023, please refer to Item 7 of Part II, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which was filed with the SEC on February 20, 2025.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
Cardiac Rhythm Management & Neuromodulation (“CRM&N”) sales for 2025 increased $8.2 million, or 1%, in comparison to 2024, with Cardiac Rhythm Management and Neuromodulation growing at market, offset by the planned decline of an early spinal cord simulation neuromodulation finished implantable pulse generator (non-emerging) customer, announced in 2020. Foreign currency exchange rate fluctuations did not have a material impact on CRM&N sales for 2025 in comparison to 2024.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
(a)Compensation and benefits increased primarily due to annual merit increases, acquisitions, leadership transition costs, and enterprise resource planning (“ERP”) implementation costs. Leadership transition costs primarily include incremental costs associated with executive leadership transitions. ERP implementation costs relate to direct and incremental costs incurred in connection with our multi-phase implementation of a new ERP solution and the related technology infrastructure costs.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
The provision for income taxes was $22.6 million and $26.5 million for the years ended December 31, 2025 and 2024, respectively. The decrease in the tax provision was primarily due to lower net income before taxes, a recognized increase in the impact of deductible stock based compensation, net of limitations, an increase in R&D tax credits and tax benefits associated with realized foreign tax credits, the year over year change in unrecognized tax benefits, and the impact of earnings realized in foreign jurisdictions with statutory rates that are different than the U.S. federal statutory rate, partially offset by the impact of the net nondeductible induced conversion expenditures incurred as a result of the induced conversion from the exchange of the 2028 Convertible Notes and an increase in global minimum tax (Pillar 2).
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
Cash and cash equivalents at December 31, 2025 decreased by $29.4 million from December 31, 2024. Cash generated by operating activities of $196.1 million was primarily offset by purchases of property, plant and equipment of $91.0 million, $50.0 million of repurchases of common stock, and tax withholding payments related to net share settlements of restricted stock unit awards of $16.9 million. The payment of the cash portion of the purchase price for each of the 2025 acquisitions totaling $178.9 million was fully funded by borrowings on our Revolving Credit Facility. Net proceeds of $976.1 million from the issuance of our 2030 Convertible Notes were utilized to purchase capped call options relating to the 2030 Convertible Notes, exchange of a portion of our 2028 Convertible Notes, and pay down our Revolving Credit Facility and TLA Facility. Net of the above noted acquisition and debt-related activity, we paid a net principal amount of $68.0 million on our Senior Secured Credit Facility in 2025.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RemovedMD&A
•Valuation of goodwill, indefinite-lived intangible assets and long-lived assets
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
On October 1, 2023, we acquired substantially all of the assets and assumed certain liabilities of InNeuroCo, a recognized leader in neurovascular catheter innovation with strong development and manufacturing capabilities. InNeuroCo’s expertise and highly differentiated neurovascular catheter innovation complements our existing capabilities and market focus. Consistent with our strategy, the addition of InNeuroCo further increased our ability to provide enhanced solutions to our customers in the neurovascular catheter space.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
On April 6, 2022, we acquired Aran, a recognized leader in proprietary medical textiles, high precision biomaterial coverings and coatings as well as advanced metal and polymer braiding, Aran delivers development and manufacturing solutions for implantable medical devices. The acquisition of Aran further increased our ability to offer complete solutions for complex delivery and therapeutic devices in high growth cardiovascular markets such as structural heart, neurovascular, peripheral vascular, and endovascular as well as general surgery.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
During 2022, we announced plans to exit our portable medical market (the “Portable Medical Exit”) to enhance profitability and reallocate manufacturing capacity to support growth. Since that time, we have been working closely with impacted customers to support the transition of these products to other suppliers. Due to quality and regulatory requirements, we expected it would take three to four years to complete this transition. We currently expect Portable Medical sales to begin to wind down with the final sales and market exit occurring in 2025. Portable Medical sales are included in our Other Markets product line sales.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
As a result of the Electrochem divestiture, the results of operations of the Electrochem business have been classified as discontinued operations for all periods presented. Intersegment sales to Electrochem that were previously eliminated in consolidation have been treated as third-party sales and are included in sales from continuing operations as we will continue to supply the Electrochem business with certain specified products following its divestiture. Prior period amounts have been reclassified to conform to the continuing operations reporting presentation.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
The following discussion is a comparison between results for the years ended December 31, 2024 and 2023.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
During the fourth quarter of 2024, we began referring to our “Advanced Surgical, Orthopedics & Portable Medical” product line as the “Other Markets” product line, to better capture the evolving nature of our products and ongoing strategic focus. The name change has no impact on financial information previously reported.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
Cardiac Rhythm Management & Neuromodulation (“CRM&N”) sales for 2024 increased $47.7 million, or 8%, in comparison to 2023. CRM&N sales for 2024 were driven by double-digit neuromodulation growth from emerging customers with premarket approval products and normalized low single-digit cardiac rhythm management growth.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
(a)Compensation and benefits increased primarily due to annual merit increases and an increase in headcount related to the recent Pulse and InNeuroCo acquisitions.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
(e)The increase in bank fees and charges was driven by increased fees related to our factoring and supplier financing arrangements, primarily due to higher volume under both arrangements during 2024 compared to 2023.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
2024 2023 Change Restructuring charges(a) 4,013 5,874 (1,861) Acquisition and integration costs(b) 8,941 3,444 5,497 Other general expenses(c) (805) 2,110 (2,915) Total restructuring and other charges $ 12,149 $ 11,428 $ 721
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
The impact of foreign currency exchange rates on transactions denominated in foreign currencies included in Other (income) loss, net for 2024 and 2023 were net losses of $3.2 million and $1.0 million, respectively. We continually monitor our foreign currency exposures and seek to take steps to mitigate these risks. However, fluctuations in foreign currency exchange rates could have a significant impact, positive or negative, on our financial results in the future.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RewordedMD&A
The increase Operating Activities - During 2025, we generated cash from operations of $25.0 $196.1 million, compared to $205.2 million was the result of in 2024, as a $27.3 $56.7 million increase in net income adjusted for non-cash items such as depreciation and amortization, partially amortization was offset by a $2.3 $65.8 million decrease in cash flow provided by changes in operating assets and liabilities.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
In addition, Amount for 2024 includes loss recoveries of $1.2 million recorded during the 2023 amount includes $2.0 million second quarter of property loss and related expenses resulting from 2024 relating to property damage which occurred in the fourth quarter of 2023 at one of our manufacturing facilities.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
Our future results of operations and liquidity could be materially adversely affected by uncertainty surrounding macroeconomic and geopolitical factors in the U.S. and globally characterized by the supply chain environment, inflationary pressure, elevated changes in interest rates, disruptions in the commodities’ markets or in supply chain as a result of the conflict between Russia and wars in Ukraine and conflicts in the Middle East, including Israel and Iran, the tensions in Asia relating to China and Taiwan, and the introduction of or changes in tariffs or trade barriers.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
Investing Activities – The $32.0 $75.3 million increase in net cash used in investing activities was primarily attributable to an increase in net cash paid for acquisitions, acquisitions and a decrease of cash received from the 2024 sale of Electrochem, partially offset by decreased purchases of property, plant and equipment and net cash proceeds from the sale of Electrochem. equipment.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
However, a significant increase in the discount rate, decrease in the terminal growth rate, increase in tax rates, decrease in the royalty rate or substantial reductions in our end-markets and volume assumptions, or increases in our cost assumptions could have a negative impact on the estimated fair values of either value of our tradenames reporting unit and require us to recognize impairments of these indefinite-lived intangible assets an impairment loss in a future period.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
Subsequent to the end of the 2024, on On January 7, 2025, we acquired substantially all of the assets and assumed certain liabilities of certain subsidiaries of Katahdin Industries, Inc., including its main operating subsidiary, Precision Coating LLC (collectively “Precision”). Precision.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
Other (income) loss, net primarily includes gains/losses reflects certain items not directly related to our core operations, including foreign currency gains and losses from the impact of exchange rates on transactions denominated in foreign currencies. currencies and other non-core items.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
(b)Amount Amount for 2024 primarily includes acquisition expenses of $5.5 million, primarily related to the Pulse and Precision Coating (completed in January 2025) acquisitions, and $3.4 million of integration expenses of $3.4 million, primarily related to the InNeuroCo and Pulse acquisitions. expenses.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
For the Greatbatch Medical tradename, the The excess of the estimated fair value over carrying value (expressed as a percentage of carrying value) was significantly in excess of its carrying value of $20 million by approximately 354% as of December 31, 2024. 2025.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
Other Markets sales for 2024 were flat 2025 decreased $28.7 million, or 27%, in comparison to 2023, as 2024, driven by the decline in Portable Medical from the multi-year exit announced in 2022 was offset by the Pulse acquisition. 2022.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
Investing activities for 2024 included 2025 include net cash paid of $178.9 million for the Precision, VSi and Biocoat acquisitions, compared to net cash paid of $138.5 million during 2024 for the Pulse acquisition.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
Electrochem, (“Electrochem”), which focused on nonmedical applications for the energy, military and environmental sectors, represented substantially all of the assets and operations in our previously reported Non-Medical reporting segment. sectors.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new